I
Isaac P. Forquer
Researcher at Veterans Health Administration
Publications - 16
Citations - 1581
Isaac P. Forquer is an academic researcher from Veterans Health Administration. The author has contributed to research in topics: Plasmodium falciparum & Coenzyme Q – cytochrome c reductase. The author has an hindex of 14, co-authored 16 publications receiving 1413 citations. Previous affiliations of Isaac P. Forquer include Oregon Health & Science University & Drexel University.
Papers
More filters
Journal ArticleDOI
Chemical genetics of Plasmodium falciparum.
W. Armand Guiguemde,Anang A. Shelat,David Bouck,Sandra Duffy,Gregory J. Crowther,Paul H. Davis,David C. Smithson,Michele Connelly,Julie Clark,Fangyi Zhu,María Belén Jiménez-Díaz,María Santos Martínez,Emily Wilson,Abhai K. Tripathi,Jiri Gut,Elizabeth R. Sharlow,Ian Bathurst,Farah El Mazouni,Joseph W. Fowble,Isaac P. Forquer,Paula L. McGinley,Steve Castro,Iñigo Angulo-Barturen,Santiago Ferrer,Philip J. Rosenthal,Joseph L. DeRisi,David J. Sullivan,John S. Lazo,David S. Roos,Michael K. Riscoe,Margaret A. Phillips,Pradipsinh K. Rathod,Wesley C. Van Voorhis,Vicky M. Avery,R. Kiplin Guy +34 more
TL;DR: A phenotypic forward chemical genetic approach to discover new antimalarial chemotypes and structures and biological activity of the entire library are disclosed, many of which showed potent in vitro activity against drug-resistant P. falciparum strains.
Journal ArticleDOI
Quinolone-3-Diarylethers: A New Class of Antimalarial Drug
Aaron Nilsen,Alexis N. LaCrue,Karen L. White,Isaac P. Forquer,R. Matthew Cross,Jutta Marfurt,Michael W. Mather,Michael J. Delves,David M. Shackleford,Fabián E. Sáenz,Joanne M. Morrisey,Jessica Anne Steuten,Tina Mutka,Yuexin Li,Grennady Wirjanata,Eileen Ryan,Sandra Duffy,Jane X. Kelly,Boni F. Sebayang,Anne-Marie Zeeman,Rintis Noviyanti,Robert E. Sinden,Clemens H. M. Kocken,Ric N. Price,Ric N. Price,Vicky M. Avery,Iñigo Angulo-Barturen,María Belén Jiménez-Díaz,Santiago Ferrer,Esperanza Herreros,Laura M. Sanz,Francisco-Javier Gamo,Ian Bathurst,Jeremy N. Burrows,Peter Siegl,R. Kiplin Guy,Rolf W. Winter,Akhil B. Vaidya,Susan A. Charman,Dennis E. Kyle,Roman Manetsch,Michael K. Riscoe +41 more
TL;DR: ELQ-300, a 4(1H)-quinolone-3-diarylether, which targets the liver and blood stages, including the forms that are crucial to disease transmission (gametocytes, zygotes, and ookinetes), has potential as a new drug for the treatment, prevention, and, ultimately, eradication of human malaria.
Journal ArticleDOI
Endochin-like quinolones are highly efficacious against acute and latent experimental toxoplasmosis
J. Stone Doggett,Aaron Nilsen,Isaac P. Forquer,Keith W. Wegmann,Lorraine Jones-Brando,Robert H. Yolken,Claudia Bordón,Susan A. Charman,Kasiram Katneni,Tracey L. Schultz,Jeremy N. Burrows,David J. Hinrichs,Brigitte Meunier,Vern B. Carruthers,Michael K. Riscoe +14 more
TL;DR: ELQ-271 and ELQ-316 are orally bioavailable drugs that are effective against acute and latent toxoplasmosis, likely acting as inhibitors of the Qi site of the T. gondii cytochrome bc1 complex.
Journal ArticleDOI
Discovery, Synthesis, and Optimization of Antimalarial 4(1H)-Quinolone-3-Diarylethers
Aaron Nilsen,Galen P. Miley,Isaac P. Forquer,Michael W. Mather,Kasiram Katneni,Yuexin Li,Sovitj Pou,April M. Pershing,Allison M. Stickles,Eileen Ryan,Jane X. Kelly,J. Stone Doggett,Karen L. White,David J. Hinrichs,Rolf W. Winter,Susan A. Charman,Lev N. Zakharov,Ian Bathurst,Jeremy N. Burrows,Akhil B. Vaidya,Michael K. Riscoe,Michael K. Riscoe +21 more
TL;DR: It is revealed that the substitution pattern on the benzenoid ring of the quinolone core significantly influenced reactivity with the host enzyme, which led to the rational design of highly selective ELQs with outstanding oral efficacy against murine malaria that is superior to established antimalarials chloroquine and atovaquone.
Journal ArticleDOI
Similar transition states mediate the Q-cycle and superoxide production by the cytochrome bc1 complex
Isaac P. Forquer,Raul Covian,Michael K. Bowman,Michael K. Bowman,Bernard L. Trumpower,David Kramer +5 more
TL;DR: Three possible general models are tested to account for the behavior of the quinol oxidase site, where the rate-limiting step for both Q-cycle and superoxide production is essentially identical, consistent with model 1 but requiring modifications to models 2 and 3.